Demand is growing for high potent APIs (HPAPIs) to treat greater numbers of patients with serious diseases, with oncology a key area.
However, there are considerable complexities involved with manufacturing HPAPIs and particular caution is required due to the toxicity of materials. Any manufacturing of APIs requires experienced specialists.
Internationally respected CDMO Indena covers every aspect of HPAPI manufacturing from late-preclinical to clinical and commercial phases.
In this webinar, we look at the current trends and challenges impacting HPAPIs from three different perspectives. Indena representatives will provide insight for:
– R&D: where it all begins for HPAPIs
– Technical operations: Manufacturing once process development has been defined
– Business development: The market for HPAPIs. How it’s going to grow and the types of investments